Original InvestigationCardiovascular Risks of Hydroxychloroquine vs Methotrexate in Patients With Rheumatoid Arthritis
Under an Elsevier user license
open archive
Central Illustration
Key Words
administrative data
cardiovascular
disease-modifying antirheumatic drugs (DMARDs)
pharmacoepidemiology
rheumatoid arthritis
Abbreviations and Acronyms
ASCVD
atherosclerotic cardiovascular disease
DMARD
disease-modifying antirheumatic drugs
HF
heart failure
ICD
International Classification of Diseases
MACE
3-point major adverse cardiovascular event
NDI
National Death Index
PPV
positive predictive value
PS
propensity score
RD
rate difference
SCA/VA
sudden cardiac arrest or ventricular arrythmia
Cited by (0)
Listen to this manuscript's audio summary by Editor-in-Chief Dr Valentin Fuster on www.jacc.org/journal/jacc.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center.
© 2022 by the American College of Cardiology Foundation. Published by Elsevier.